Secondary endpoints of trials of the anti-TSLP Tezepelumab examined outcomes in T2-high vs. T2-low groups and found benefits across asthma endotypes defined in part by serum IgE levels > 100 IU/mL (T2 high) or < 100 IU/mL (T2 low) [27,28]. Here, IGHE is linked to asthma.